Disorders of Fatty Acid Oxidation in the Era of Tandem Mass Spectrometry in Newborn Screening

Newborn and Infant Nursing Reviews

Volumn 8, Issue 1, 2008, Pages 18-29

  Banta Wright, Sandra A ^a   Shelton, Kathleen C ^a   Bennett, Michael J ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Fatty acid oxidation; Tandem mass spectrometry

Indexed keywords

EID: 39049136977     PISSN: 15273369     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.nainr.2007.12.014     Document Type: Article

References (88)

1. Guthrie R., and Susi A. A simple phenylalanine method for detecting PKU in large, populations of newborn infants. Pediatrics 32 (1963) 338-343
2. Beasley M., Costello P., and Smith I. Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. Q J Med 87 (1994) 155-160
3. MacGready R.A., and Hussey M.G. Newborn phenylketonuria detection program in Massachusetts. Am J Public Health 54 (1964) 2075
4. National Research Council, and Committee for the study of inborn errors of metabolism. Genetic screening: programs, principles, and research (1975), National Academy of Science, Washington, DC
5. Newborn Screening Task Force. Serving the family from birth to the medical, home: a report from the newborn screening task force. Pediatrics 106 (2000) S383-S427
6. Paul D.B. The history of phenylketonuria screening in the US. In: Holtzman N.A., and Watson M.S. (Eds). Promoting safe and effective genetic testing in the United States: final report of the Task Force on Genetic Testing (1997), National Institute of Health, Bethedsa (MD)
7. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Screening and counseling for genetic conditions: a report on the ethical, social and legal implications of genetic screening and counseling, and education programs (1983), Government Printing Office, Washington DC
8. Wilson J.M.G., and Jungner F. Principles and practice of screening for disease (Public Health Paper #34) (1968), World Health Organization, Geneva
9. American Academy of Pediatrics. Issues in newborn screening. Pediatrics 89 (1992) 135-146
10. Therrell B.L., Panny S.R., Davidson A., et al. U.S. newborn screening system, guidelines: statement of the Council of Regional Networks for Genetic Services. Screening 1 (1992) 135-147
11. Comeau A.M., Hsu H.W., Schwerzlwe M., et al. Detection of HIV in specimens from newborn screening programs. N Engl J Med 326 (1992) 1703
12. Schoen E.J., Black S., Cohen D., et al. Screening for neonatal toxoplasmosis. N Engl J Med 331 (1994) 1456-1458
13. Postellon D.C. Screening for congenital hypothyroidism. J Pediatr 9 (1981) 170-171
14. Levy H.L., and Hammersen G. Newborn screening for galactosemia and other galactose metabolic defects. J Pediatr 92 (1978) 871-877
15. Waggoner D.D., Buist N.R., and Donnell G.N. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 13 (1990) 802-818
16. Millington D.S., Roe C.R., and Maltby D.A. Application of high resolution fast atom bombardment and constant B/E ration linked scanning to the identification and analysis of acylcarnitines in metabolic disease. Biomed Mass Spectrom 11 (1984) 236-241
17. Millington D.S., Kodo N., Norwood D.L., and Roe C.R. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 13 (1990) 321-324
18. Millington D.S., and Koeberl D. Metabolic screening in the newborn. Growth Genet Horm 19 (2003) 33-38
19. Zytkovicz T.H., Fitzgerald E.F., Marsden D., et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two year summary from the New England Newborn Screening Program. Clin Chem 47 (2001) 1945-1955
20. Rashed M.S., Rahbeeni Z., and Ozand P.T. Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol 23 (1999) 183-193
21. Millington D.S., Terade N., Chace D.H., et al. The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. In: Coates P.M., and Tanaka K. (Eds). New development in fatty acid oxidation: proceedings of the second International Symposium on clinical, biochemical, and molecular aspects of fatty acid oxidation (1991), Wiley-Liss, New York 339-354
22. Chace D.H., Millington D.S., Terada N., et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem 39 (1993) 66-71
23. Schmidt-Sommerfeld E., Penn D., Duran M., et al. Detection of inborn errors of fatty acid oxidation from acylcarnitine analysis of plasma and blood spots with radioisotopic exchange-high-performance liquid chromatographic method. J Pediatr 122 (1993) 708-714
24. Van Hove J.L., Zhang W., Kahler S.G., et al. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. Am J Hum Genet 52 (1993) 958-966
25. Chace D.H., Hillman S.L., Millington D.S., et al. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem 41 (1995) 62-68
26. Millington D.S. Tandem mass spectrometry in clinical diagnosis. In: Blau N., Duran M., Blaskovics M.E., and Gibson K.M. (Eds). Physician's guide to the laboratory Diagnosis of metabolic diseases. 2nd ed. (2003), Springer, Berlin, Germany 57-85
27. Sewell A.C., and Bohles H.J. Acylcarnitines in intermediary metabolism. Eur J Pediatr 154 (1995) 871-877
28. Carter A.L., Abney T.O., and Lapp D.F. Biosynthesis and metabolism of carnitine. J Child Neurol 10 Suppl 2 (1995) S3-S7
29. Chace D.H., Hillman S.L., Van Hove J.L., et al. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 43 (1997) 2108-2113
30. Ziadeh R., Hoffman E.P., Finegold D.N., et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 37 (1995) 675-678
31. American College of Medical Genetics. Standardization of outcomes and guidelines for state newborn screening program. Fed Regist 70 (2005). Department of Health and Human Services. Available at: www.mchc.hrsa.gov/screening/summary.htm. [Retrieved July 30, 2007]
32. Bennett M.J. The enzymes of mitochondrial fatty acid oxidation. Clin Chim Acta 226 (1994) 213-224
33. Krebs H.A. The history of the tricarboxylic acid cycle. Perspect Biol Med 14 (1970) 154-170
34. McGarry J.D., and Brown N.F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244 (1997) 1-14
35. Brown N.F., Mullur R.S., Subramanian I., et al. Molecular characterization of L-CPT I deficiency in six patients: insight into function of the native enzyme. J Lipid Res 42 (2001) 1134-1142
36. Bougneres P.F., Saudubray J.M., Marsac C., et al. Fasting hypoglycemia resulting from hepatic carnitine palmitoyltransferase deficiency. J Pediatr 98 (1981) 742-746
37. Bonnefont J.P., Haas R., Wolff R., et al. Deficiency of carnitine palmitoyltransferase I. J Child Neurol 4 (1989) 198-203
38. Bougneres P.F., Saudubray J.M., Marsac C., et al. Decreased ketogenesis due to deficiency of hepatic carnitine acyltransferase. N Engl J Med 302 (1980) 123-124
39. Fingernut R., Roschinger W., Muntau A.C., et al. Hepatic palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem 47 (2001) 1763-1768
40. Prip-Buus C., Thuiller L., Abadi N., et al. Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community. Mol Genet Metab 73 (2001) 46-54
41. Prasad C., Johnson J.P., Bonnefont J.P., et al. Hepatic carnitine palmitoyltransferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA based newborn screening program. Mol Genet Metab 73 (2001) 55-63
42. Seargeant L.E., Stier A., Prasad C., et al. Preliminary evidence for high frequency of combined CPT 1 and CPT 2 mutations in the Canadian Inuit. In: IX International Congress on Inborn Errors of Metabolism, Brisbane, Australia, September 2-6, 2003. J Inherit Metab Dis 26 suppl 2 (2003) 197
43. Sinclair G., Waters P.J., Vallance H., et al. The dilemma of the CPT-1 P479L mutation in Canadian Inuit and First Nations Families. 6th International Congress on Fatty Acid Oxidation, Egmond aan Zee, the Netherlands, 21 (2005)
44. Gillingham MB, Banta-Wright SA, Bennett MJ, et al. High incidence of the carnitine palmitoyltransferase-1A P479L variant identified in Alaska native infants by expanded newborn screening. In preparation.
45. Roe C.R., and Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic and molecular bases of inherited disease. 9th ed. (2001), McGraw-Hill, New York 2297-2326
46. Maier E.M., Leibl B., Roschinger W., et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 25 (2005) 443-452
47. Chace D.H., Kalas T.A., and Naylor E.W. The application of tandem mass spectrometry in neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet 3 (2002) 17-45
48. Carpenter K., Wiley V., Sim K.G., et al. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275,000 babies. Arch Dis Child Fetal Neonatal Ed 85 (2001) F105-F109
49. Sanders S., Janze N., Janetzky B., et al. Neonatal screening for medium acyl-CoA deficiency: high incidence in lower Saxony (northern Germany). Eur J Pediatr 160 (2001) 318-319
50. 10 dicarboxylic aciduria: evidence for a defect in general acyl-CoA dehydrogenase. Clin Chim Acta 126 (1982) 53-67
51. Kidd J.R., Matsubara Y., Castiglione C.M., et al. The locus for the medium-chain acyl-coA dehydrogenase gene on chromosome 1 is highly polymorphic. Genomics 6 (1990) 89-93
52. Andresen B.S., Sobrowolski S.F., O'Reilly L., et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68 (2001) 1408-1418
53. Tajima G., Sakura N., Ono H., et al. Medium chain acyl-coA dehydrogenase deficiency found through newborn screening by tandem mass spectrometry in Japan. J Inherit Metab Dis Suppl 1 (2004) 11
54. Andresen B.S., Bross P., Udvari S., et al. The molecular basis for medium-chain acyl-coA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype?. Hum Mol Genet 6 (1997) 695-707
55. Coates P.M., Hale D.E., Stanley C.A., et al. Genetic deficiency of medium-chain acyl coenzyme a dehydrogenase: studies in cultured skin fibroblasts and peripheral mononuclear leukocytes. Pediatr Res 19 (1985) 671-676
56. Bennett M.J., Rinaldo P., Millington D.S., et al. Medium chain acyl-coA dehydrogenase deficiency: postmortem diagnosis in case of sudden infant death and neonatal diagnosis of an affected sibling. Pediatr Pathol 11 (1991) 889-895
57. Rashad M.S., Ozand P.T., Bennett M.J., et al. Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. Clin Chem 41 8 pt1 (1995) 109-111
58. Iafolla A.K., Thompson R.J., and Roe C.R. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 124 (1994) 409-415
59. Christodoulou J., Hoare J., Hammond J., et al. Neonatal onset of medium-chain acyl-coenzyme A dehydrogenase deficiency with confusing biochemical features. J Pediatr 126 (1995) 65-68
60. Wilcox R.L., Nelson C.C., Stenzel P., and Steiner R.D. Postmortem screening for fatty acid oxidation disorders by analysis of Guthrie cards with tandem mass spectrometry in sudden unexpected death in infancy. J Pediatr 141 (2002) 833-836
61. Emery J.L., Variend S., Howat A.J., et al. Investigation of inborn errors of metabolism in unexpected infant deaths. Lancet 2 (1988) 29-31
62. Harpey J.P., Charpentier C., and Paturneau-Jouas M. Sudden infant death syndrome and inherited disorders of fatty acid b-oxidation. Biol Neonate 58 Suppl 1 (1990) 70-80
63. Treem W.R., Stanley C.A., and Goodman S.I. Medium-chain acyl-CoA dehydrogenase deficiency: metabolic effects and therapeutic efficacy of long-term l-carnitine supplementation. J Inherit Metab Dis 12 (1989) 112-119
64. Stumpf D.A., Parker W.D., and Angelini C. Carnitine deficiency, organic acidemias and Reye's syndrome. Neurology 35 (1985) 1041-1045
65. Roe C.R., Millington D.S., Kahler S.G., et al. Carnitine homeostasis in the organic acidurias. In: Tanaka K., and Coates P.M. (Eds). Fatty acid oxidation: clinical, biochemical and molecular aspects (1990), Alan R. Liss, New York 382-402
66. Rinaldo R., Schmidt-Sommerfeld E., Posca A.P., et al. Effect of treatment with glycine and l-carnitine in medium-chain acyl-coenzyme a dehydrogenase deficiency. J Pediatr 122 (1993) 580-584
67. Spieketkoetter U., Tokunaga C., Wendel U., et al. Tissue carnitine homeostasis in very-long-chain acyl-CoA dehydrogenase-deficient mice. Ped Res 57 (2005) 760-764
68. Spiekerkoetter U., Sun B., Zytkovicz T., et al. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Peds 143 (2003) 335-342
69. Bertran C., Largilliere C., Zabot M.T., et al. Very-long-chain acyl-coA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Biophys Acta 1180 (1993) 327-329
70. Aoyama T., Uchida Y., Kelley R.I., et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun 191 (1993) 1369-1372
71. Izai K., Uchida Y., Orii T., and Hashimoto. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. J Biol Chem 267 (1992) 1027-1033
72. Aoyama T., Ueno I., Kamijo T., and Hashimoto T. Rat very-long-chain acyl-CoA dehydrogenase, a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid beta-oxidation system. cDNA and deduced amino acid sequence and distinct specificities of the cDNA-expressed protein. J Biol Chem 269 (1994) 19088-19094
73. Hale D.E., and Bennett M.J. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 121 (1992) 1-11
74. Yamaguchi S., Idno Y., Coates P.M., et al. Identification of very-long-chain acyl-Coa dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Ped Res 34 (1993) 111-113
75. Wood J.C., Magera M.J., Rinaldo P., et al. Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. Pediatrics 108 (2001) E19
76. Touma E.H., Rashed M.S., Vianey-Saban C., et al. A severe genotype with favourable outcome in very long chain acyl-coA dehydrogenase deficiency. Arch Dis Child 84 (2001) 58-60
77. Yoon N., Strauss A.W., and Yoo H.W. Sudden death in a Korean infant with very-long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis 24 (2001) 407-408
78. Bonnett D., Martin D., de Lonlay P., et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 100 (1999) 2248-2253
79. Hahn S.H., Lee E.H., Jung J.W., et al. Very long chain acyl coenzyme A dehydrogenase deficiency in a 5-month-old Korean boy: identification of a novel mutation. J Peds 135 (1999) 250-253
80. Boles R.G. Very long-chain acyl-CoA dehydrogenase deficiency in an infant presenting with massive hepatomegaly. J Inherit Metab Dis 25 (2002) 315-316
81. Gregersen N., Andresen B.S., Corydon M.J., et al. Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Human Mutat 12 (2001) 169-189
82. Cox K.L., Hamm D.A., Millington D.S., et al. Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet 10 (2001) 2069-2077
83. Andresen B.S., Olpin S., Poorthuis B.J.H.M., et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet 64 (1999) 479-494
84. Andresen B.S., Dobrowolski S.F., O'Reilly L., et al. Medium-chain acyl-CoA dehydrogenases (MCAD) mutations identified by MS/MS based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68 (2001) 1408-1418
85. Gregersen N., Andresen B.S., Bross P., et al. Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the MCAD gene and expression of inactive mutant protein in E coli. Hum Genet 86 (1991) 545-551
86. Cox G.F., Souri M., Aoyama T., et al. Reversal of severe hypertrophic cardiomyopathy and an excellent neurophysiologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 133 (1998) 247-253
87. Spiekerkotter U., Schwahn B., Korall H., et al. Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: monitoring of treatment by carnitine/acylcarnitine analysis in blood spots. Acta Paediatr 89 (2000) 492-495
88. National Newborn Screening and Genetic Resources Center (NNSGRC). Availableat. http://genes-r-us.uthscsa.edu/resources/newborn/screenstatus.htm. [Retrieved July 30, 2007]